SALT LAKE CITY, Dec. 20, 2017 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (NASDAQ:COOL) today officially announced that the company has continued to expand its R&D and biomedical manufacturing capabilities and moved its corporate headquarters to a 200,000 ft2 multi-facility “PolarityTE Campus.”   

Slated to open in early 2018, the new Polarity corporate campus will centralize core company departments related to basic biomedical R&D, pre-clinical research, as well as provide another site for the manufacturing of the now commercially available SkinTE™ product. The campus will also house the “TE” development hub for the Company’s pipeline of products and technology derivatives of which OsteoTE™ is set for expected commercialization in late 2018.

“With the expansive addition of the new PolarityTE campus, we hope to meet the impressive demand we have already received for SkinTE, while allowing us to grow our company, develop our core pipeline tissues and further evolve our technology platforms at an even more accelerated rate,” said Dr. Denver Lough, Chief Executive Officer of PolarityTE. “Our newly integrated headquarters and manufacturing facilities underscores PolarityTE’s commitment to growing our commercial operations and capabilities nationally, as well as our continued dedication to the development of pragmatic biomedical technologies and regenerative materials.”

About PolarityTE™
PolarityTE, Inc. is a regenerative medicine company, with a platform technology to regenerate full-thickness tissue. The Company's novel regenerative medicine platform and proprietary technology employs a patient's own cells for the healing of full-thickness, functionally-polarized tissues. If clinically successful, the PolarityTE™ platform will provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The PolarityTE™ platform leverages natural and biologically-sound principles which are readily adaptable to a wide spectrum of organ and tissue systems. This revolutionary technology, paired with the Company's world-renowned clinical advisory board, position PolarityTE™ to drastically change the field and future of translational regenerative medicine. More information can be found online at

Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company's ongoing compliance with the requirements of The NASDAQ Stock Market and the Company's ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should'" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Investor Contact
John Stetson
(385) 237-2365

Media Contacts
Scott Santiamo
Russo Partners LLC 
(718) 344-5843
David Schull
Russo Partners LLC 
(858) 717-2310